SUMMARY Thirty patients with chronic pain due to osteoarthrosis (OA) of the knee were enrolled in a randomised double-blind cross-over trial of self-administered transcutaneous electrical nerve stimulation (TENS) and placebo TENS. Medication was standardised to paracetamol tablets only. As measured on visual analogue scales for pain relief 46% of patients responded to active therapy and 43% to placebo. The length of pain relief during active therapy was significantly longer than that during placebo. At the end of the trial more patients wanted to continue using active TENS in preference to placebo or their original medication. Although most of the parameters observed favoured active TENS, it was not possible to establish its clear superiority over placebo, because the response rate to placebo TENS was high and sustained for at least 3 weeks. This trial suggests that a longer study is required to establish the role of TENS as a therapeutic agent in the treatment of the pain of chronic arthritis.
Numerous reports have been published in the last decade on the successful treatment of acute and chronic pain conditions with transcutaneous electrical nerve stimulation (TENS).`-4 This physical noninvasive therapy is now used in pain clinics in the United Kingdom.' No controlled studies, however, have been conducted which consider TENS as a primary therapy rather than as an adj unct to medication or other physical treatments.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonl1 used in the treatment of pain due to osteoarthrosis (OA) of the knee, but recentlv the value of these drugs in OA has been seriously questioned on the grounds that their expense ma' not be justified in terms of therapeutic effjcacyv and that there remains the possibility that deleterious effects may result from their use. ' In contrast to drug therapy the potential side effects of TENS are minimal (e.g., skin irritation) and contraindications (e.g.. use with cardiac pacemakers) are few. 
